OmniAb to Report Fourth Quarter 2025 Financial Results on March 4
OmniAb, Inc. (NASDAQ: OABI) will release its financial results for the quarter and year ending December 31, 2025, after the U.S. financial markets close on Wednesday, March 4, 2026. The company will also host a conference call and webcast on the same day at 4:30 p.m. Eastern time to discuss these results and provide business updates.
OmniAb to Report Fourth Quarter 2025 Financial Results on March 4
OmniAb, Inc. (NASDAQ: OABI) announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, after the U.S. financial markets close on Wednesday, March 4, 2026. The company will host a conference call on the same day at 4:30 p.m. Eastern time to discuss the results and provide business updates. A live and replay webcast with slides will also be available for interested parties.
Insider Selling: OmniAb (NASDAQ:OABI) CFO Sells 9,301 Shares of Stock
OmniAb (NASDAQ:OABI) CFO Kurt Gustafson sold 9,301 shares of the company's stock for $15,904.71 on February 18, 2026, reducing his stake by 3.34%. This sale is part of a broader pattern of insider selling by the CEO and a director around the same time, despite "Moderate Buy" analyst ratings and increased institutional ownership. The stock is currently trading around $1.71, below its 50-day and 200-day simple moving averages.
Matthew Foehr Sells 30,843 Shares of OmniAb (NASDAQ:OABI) Stock
OmniAb CEO Matthew Foehr sold 30,843 shares of OABI stock, valued at over $52,000, reducing his stake by 0.70%. The biotech company's stock trades around $1.71, with mixed analyst ratings and high institutional ownership. Other executives and a director also recently sold shares.
OmniAb (NASDAQ:OABI) Insider Charles Berkman Sells 9,673 Shares
OmniAb director Charles Berkman sold 9,673 shares for $16,540.83, reducing his stake by 2.4%. This sale is part of broader insider selling activity from the CEO and CFO, while institutional ownership remains high at 72.08%. The stock trades near $1.71, and analyst ratings are mixed, with a "Moderate Buy" consensus target of $6.67 contrasting with a Weiss "sell" rating.
Insider Selling: OmniAb (NASDAQ:OABI) Insider Sells 6,990 Shares of Stock
OmniAb (NASDAQ:OABI) insider Charles Berkman sold 6,990 shares of the company's stock for approximately $11,883 on February 17, 2026, reducing his stake by 1.79%. Following the sale, Berkman now owns 383,623 shares valued at about $652,159. The stock traded up 0.6% to $1.71, with a market cap of $246.16 million, and institutional investors own 72.08% of the shares.
OmniAb (NASDAQ:OABI) CFO Sells $11,607.60 in Stock
OmniAb CFO Kurt Gustafson sold 6,828 shares of the company's stock for $11,607.60, reducing his stake by 2.56%. The biotechnology company's stock recently traded at $1.71, with institutional investors owning about 72% and analysts holding a consensus "Moderate Buy" rating.
OmniAb (OABI) chief legal officer Berkman sells $11883 in stock
Charles S. Berkman, Chief Legal Officer of OmniAb, Inc. (NASDAQ:OABI), sold 6,990 shares of common stock for approximately $11,883 on February 17, 2026. This sale occurred after the vesting of 13,542 restricted stock units (RSUs) on February 16, 2026. Following the transaction, Berkman directly owns 383,623 shares of OmniAb common stock.
OmniAb Updates Bylaws to Align with SEC Proxy Rules
OmniAb (OABI) has updated its bylaws to align with SEC universal proxy rules, effective January 30, 2026. These revisions tighten disclosure and procedural requirements for shareholder nominations and business proposals, aiming to enhance transparency and reinforce the company's control over the nomination process. Despite significant financial challenges, OmniAb shows some optimism through positive technical indicators and strategic initiatives.
OmniAb, Inc.'s (NASDAQ:OABI) recent 10% pullback adds to one-year year losses, institutional owners may take drastic measures
OmniAb, Inc. (NASDAQ:OABI) has experienced a 10% stock pullback recently, contributing to a 42% loss over the past year. Institutional investors, who hold a significant 36% ownership and endured the highest losses, may consider drastic measures if the decline continues. Hedge funds and private equity firms also hold substantial stakes, indicating multiple influential parties involved in the company's ownership structure.
OmniAb’s Earnings Call: Progress Amid Challenges
The article from MSN appears to be a placeholder or has missing content, as it only contains the title "OmniAb’s Earnings Call: Progress Amid Challenges" and the source "MSN" without any body text. Therefore, it is impossible to summarize any detailed information about OmniAb's earnings call or the progress and challenges mentioned in the title. The content provided is insufficient to extract any meaningful financial data, company performance, or analyst perspectives.
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and OmniAb (OABI)
Two analysts have issued bullish sentiments on healthcare companies Novan (NOVN) and OmniAb (OABI). While the article mentions Novan, it only provides details for OmniAb, where analyst Matt Hewitt from Craig-Hallum maintained a Buy rating, noting a consensus of Strong Buy with a $6.75 price target.
Launch of OmniUltra Expands OmniAb’s Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies
OmniAb, Inc. (NASDAQ: OABI) has launched its new OmniUltra™ platform, the first transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, at the 2025 Antibody Engineering & Therapeutics Conference. This innovative platform broadens therapeutic opportunities beyond conventional antibodies and introduces picobodies™, the smallest known natural antibody-derived binding domain. OmniUltra is designed to deliver pre-optimized specificity, affinity, and structural stability for various applications, reinforcing OmniAb's leadership in drug discovery innovation.
Launch of OmniUltra Expands OmniAb’s Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies
OmniAb, Inc. has launched its new OmniUltra™ platform, the industry's first transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework. This platform broadens therapeutic opportunities beyond conventional antibodies, enabling the discovery of novel binding modes and access to challenging targets, and facilitating applications in areas like bispecifics, multispecifics, CAR-T, and stand-alone peptide therapeutics. OmniUltra also allows for the isolation of picobodies™, the smallest natural antibody-derived binding domains, and represents a pioneering advancement in antibody and peptide discovery.
OmniAb Insiders Enjoying US$277k Appreciation On US$1.59m Investment
OmniAb (NASDAQ: OABI) insiders who invested US$1.59 million in the last year have seen their holdings appreciate by US$277,000, thanks to a 10% stock gain. This included a significant US$1 million purchase by President Matthew Foehr at a price below the current market value, suggesting insiders see value in the company. Overall, insiders bought more shares than they sold, and their collective ownership stands at 12%, aligning their interests with other shareholders.
OmniAb Insiders Enjoying US$277k Appreciation On US$1.59m Investment
Insiders at OmniAb, Inc. have seen a significant appreciation of US$277k on their US$1.59m investment over the last 12 months, largely due to a 10% stock gain. While individual transactions vary, there has been more insider buying than selling, indicating confidence in the company, despite it currently incurring losses. Insiders own 12% of the company, suggesting good alignment with shareholders.
OmniAb Insiders Enjoying US$277k Appreciation On US$1.59m Investment
Insiders at OmniAb, Inc. (NASDAQ:OABI) have seen a US$277k appreciation on their US$1.59m investment over the last year, coinciding with a 10% increase in the company's market value. While one significant purchase was made below the current price, overall insider buying exceeded selling, indicating confidence in the company's future despite current losses. Insiders collectively own 12% of OmniAb, aligning their interests with other shareholders.
OmniAb unveils OmniUltra chickens at antibody conference
OmniAb debuted its new OmniUltra platform at the Antibody Engineering & Therapeutics conference, showcasing transgenic chickens that produce ultralong CDRH3 antibodies. This innovative technology promises broad epitope coverage and enhanced precision for targeting conserved mammalian proteins, potentially revolutionizing therapeutic approaches. The development builds upon OmniAb's strategic partnerships and commitment to advancing antibody discovery platforms.
Foehr, OmniAb CEO, sells $27k in shares
OmniAb, Inc. President and CEO Matthew W. Foehr recently sold 13,666 shares of common stock for approximately $26,785, following the exercise of options to acquire additional shares. Despite a decrease in Q3 revenue and a net loss, the company's shares have shown significant momentum with recent gains, and analysts project potential upside from current levels. OmniAb maintains a strong financial position, holding more cash than debt and a robust current ratio, even though it is not yet profitable.
OmniAb (NASDAQ:OABI) CEO Sells $26,785.36 in Stock
OmniAb, Inc.'s (NASDAQ:OABI) CEO, Matthew Foehr, sold 13,666 shares of the company's stock on December 8th for a total of $26,785.36, decreasing his stake by 0.31%. Despite the sale, OmniAb's stock currently holds a "Moderate Buy" consensus rating from analysts, with a target price of $6.67, though Weiss Ratings reiterated a "sell" rating. The company recently reported quarterly EPS of ($0.14), beating estimates by $0.01, but missed revenue expectations.
OmniAb CFO Gustafson sells $46,887 in shares
OmniAb's CFO, Kurt A. Gustafson, sold 23,922 shares of common stock worth $46,887 to cover tax obligations related to restricted stock unit vesting. This transaction occurred after a week where OmniAb shares gained 16.37%, with the company maintaining a strong financial position despite a recent decline in revenue reported in Q3. Analyst targets for OmniAb shares range from $3 to $11.
Here's Why We're Not Too Worried About OmniAb's (NASDAQ:OABI) Cash Burn Situation
OmniAb (NASDAQ:OABI) has a cash runway of about 20 months, having burnt through US$35m in the last year against US$60m in cash reserves. Analysts project the company will hit cashflow breakeven in around 22 months, suggesting they may not need to raise additional capital. Despite flat revenue over the past year, a 25% reduction in cash burn and a manageable cash burn relative to market capitalization ($35m burn vs $286m market cap) contribute to a positive outlook regarding its financial health.
OmniAb CFO Gustafson sells $46,887 in shares By Investing.com
OmniAb's CFO, Kurt A. Gustafson, sold 23,922 shares of common stock for $46,887 to cover tax obligations related to restricted stock units (RSUs). This transaction occurred after OmniAb shares saw a significant gain, with Gustafson also acquiring 46,500 shares through RSU vesting. Despite a recent revenue decrease, investor sentiment appears optimistic, evidenced by an aftermarket stock price rise.
OmniAb (OABI) chief legal officer Berkman sells $15,766 in stock By Investing.com
OmniAb's Chief Legal Officer, Charles S. Berkman, sold 8,044 shares of common stock for approximately $15,766 to cover tax withholding obligations after the vesting of restricted stock units. Despite this transaction, which was not a discretionary trade, OmniAb's stock has shown significant recent momentum. The company reported a decline in Q3 revenue and a net loss, but its strategic plans have maintained investor confidence, with its stock trading near its Fair Value estimate.
OmniAb (NASDAQ:OABI) Insider Charles Berkman Sells 8,044 Shares
OmniAb (NASDAQ:OABI) insider Charles Berkman sold 8,044 shares of the company's stock on December 8th at an average price of $1.96, totaling $15,766.24. This transaction reduced his stake by 2.09% to 377,071 shares. Despite the insider sale and recent revenue miss, analysts maintain a "Moderate Buy" consensus rating with a $6.67 price target, while Weiss Ratings reissued a "sell (d-)" rating.
OmniAb Executives Sell Shares to Cover Tax Obligations
Several OmniAb executives, including CEO Matthew W. Foehr, Chief Legal Officer Charles S. Berkman, and Executive VP of Finance Kurt A. Gustafson, recently sold company shares. These sales were made to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs) at a weighted average price of $1.96 per share. The transactions involved significant amounts, with Foehr selling 13,666 shares, Berkman selling 8,044 shares, and Gustafson selling 23,922 shares.
OmniAb (NASDAQ:OABI) CFO Sells $46,887.12 in Stock
OmniAb's CFO, Kurt Gustafson, sold 23,922 shares of the company's stock for $46,887.12 on December 8th, reducing his stake by 8.65%. The biotech company, trading near $1.99, has a market cap of $286.5 million and reported a loss of $0.14 EPS last quarter, missing revenue estimates. Despite institutional ownership of 72.08% and a "Moderate Buy" consensus rating from analysts, Weiss Ratings reiterated a "sell (D-)" opinion.
Diretor jurídico da OmniAb (OABI) vende ações no valor de US$ 15.766
O diretor jurídico da OmniAb (OABI), Charles S. Berkman, vendeu 8.044 ações ordinárias por aproximadamente US$ 15.766 para cobrir obrigações fiscais relacionadas ao vencimento de unidades de ações restritas. Após a transação, Berkman detém 377.071 ações ordinárias. A OmniAb registrou uma queda na receita e um prejuízo líquido no terceiro trimestre, mas suas ações demonstraram um impulso de 16,37% na última semana, negociando perto de seu Valor Justo.
OmniAb to Hold OmniUltra Virtual Investor Event on December 15
OmniAb, Inc. (NASDAQ: OABI) announced it will host a virtual investor event on December 15, 2025, at 5:00 p.m. Eastern time to launch OmniUltra. This event will introduce OmniAb's newest technology, OmniUltra, which is a transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, highlighting its market applications and strategic importance. The event will include a review of the technology, its applications, and its strategic importance to the business.
OmniAb to Hold OmniUltra Virtual Investor Event on December 15
OmniAb, Inc. (NASDAQ: OABI) announced it will host a virtual investor event on December 15, 2025, at 5:00 p.m. Eastern time to launch its new OmniUltra™ technology. OmniUltra is a transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, and the event will detail its market applications and strategic importance.
OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors
OmniAb, Inc. has signed a license and services agreement with Mabtrx Biosciences, a joint venture between ArrowMark Partners and Viking Global Investors. The agreement focuses on antibody discovery using OmniAb's Omni dAb™ single domain technology, for which OmniAb will receive revenue, potential equity, and royalties. This partnership highlights OmniAb's strategy to leverage its transgenic chicken-based technologies for value creation in new biotech ventures.
OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors
OmniAb, Inc. has signed a license and services agreement with Mabtrx Biosciences, a subsidiary of a joint venture between ArrowMark Partners and Viking Global Investors. The agreement focuses on Omni dAb™ single domain technology for novel antibody discovery programs. OmniAb will receive revenue for discovery services, along with potential equity and royalties from Mabtrx.
OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors
OmniAb, Inc. has signed a license and services agreement with Mabtrx Biosciences, a joint venture formed by ArrowMark Partners and Viking Global Investors, for novel OmniAb-derived antibody discovery programs. This agreement will generate revenue for OmniAb through discovery services, potential equity, and royalties. The partnership highlights OmniAb's strategy to leverage its transgenic chicken-based technologies for value creation in biotech.
OmniAb, Inc. (OABI) Expected to Beat Earnings Estimates: Should You Buy?
OmniAb, Inc. (OABI) is expected to show a year-over-year increase in earnings and revenues for the quarter ending September 2025, with results anticipated around November 4. The company's Most Accurate Estimate is higher than the Zacks Consensus Estimate, and with a Zacks Rank of #2, OmniAb, Inc. is highly likely to beat consensus EPS estimates. Investors are advised to consider other factors alongside the positive Earnings ESP and strong Zacks Rank.
OmniAb director Higgins buys shares worth $107,706
John L. Higgins, a director at OmniAb, Inc. (NASDAQ:OABI), recently purchased 77,261 shares of the company's common stock for a total of $107,706. These transactions occurred on November 6 and 7, 2025, with shares bought at prices ranging from $1.33 to $1.45, near the stock's 52-week low, following a nearly 70% decline over the past year. Despite the insider buying and the stock being considered undervalued by InvestingPro, the company expects to report earnings soon and analysts have not changed their ratings.
OmniAb, Inc. (NASDAQ:OABI) Q3 2025 Earnings Call Transcript
OmniAb, Inc. reported its Q3 2025 financial results, with revenue of $2.2 million and a net loss of $16.5 million. The company announced the upcoming launch of OmniUltra, a new transgenic chicken platform for antibody and peptide therapeutic discovery, and provided updates on its xPloration partner access program and clinical pipeline advancements. Financial guidance for 2025 was updated, with expected revenue between $18 million and $22 million and operating expenses between $82 million and $86 million.
OmniAb Inc reports results for the quarter ended September 30 - Earnings Summary
OmniAb Inc (OABI) reported a quarterly adjusted loss of 14 cents per share for the quarter ending September 30, meeting analyst expectations. Revenue for the quarter fell by 70.8% to $1.22 million, significantly missing analysts' expectations of $5.64 million. The company's shares have fallen 7.5% this quarter and 58.2% year-to-date, despite an average analyst rating of "buy" with a median 12-month price target of $10.00.
Earnings call transcript: OmniAb Q3 2025 sees revenue dip and stock uptick
OmniAb Inc. reported a significant revenue drop in Q3 2025, falling to $2.2 million from $4.2 million year-over-year, alongside a net loss of $16.5 million. Despite this, the stock saw a 2.36% uptick in aftermarket trading due to investor optimism over strategic initiatives like the OmniUltra platform launch and a $30 million private placement. The company is focusing on innovation, operational efficiency, and anticipates five new clinical programs in 2025, projecting OmniUltra to boost future earnings and cash flow.
Leerink Partnrs Issues Positive Estimate for OmniAb Earnings - Defense World
Leerink Partners has issued a positive forecast for OmniAb, Inc.'s earnings, anticipating $0.05 EPS for the current fiscal quarter. Other institutional investors have also significantly adjusted their holdings in OmniAb, with several increasing their positions. The company, a biotechnology firm, specializes in therapeutic antibody discovery technologies.
OmniAb to Participate in Three Investor Conferences in November 2025 - BioSpace
OmniAb, Inc. announced its participation in three investor conferences in November 2025. CEO Matt Foehr and CFO Kurt Gustafson will engage in one-on-one meetings and corporate presentations at events hosted by Truist Securities, Stifel, and Jefferies. These conferences provide OmniAb with opportunities to interact with investors and present its cutting-edge discovery research technology.
OmniAb to Participate in Three Investor Conferences in November - Yahoo Finance
OmniAb, Inc. (NASDAQ: OABI) announced its participation in three investor conferences in November 2025. CEO Matt Foehr and CFO Kurt Gustafson will engage in one-on-one meetings and corporate presentations at the Truist Securities BioPharma Symposium, Stifel 2025 Healthcare Conference, and Jefferies Global Healthcare Conference in London. The company will highlight its antibody discovery research technology.
OmniAb to Participate in Three Investor Conferences in November - FinancialContent
OmniAb, Inc. (NASDAQ: OBNT) announced it will participate in three investor conferences in November, including the Stifel Healthcare Conference, Jefferies London Healthcare Conference, and Evercore ISI HealthCONx Conference. Management will engage in one-on-one meetings and present at these events, which will be accessible via webcast.
OmniAb (NASDAQ:OABI) Receives Sell (E+) Rating from Weiss Ratings - Defense World
OmniAb (NASDAQ:OABI) has received a Sell (E+) rating from Weiss Ratings. Royal Bank of Canada also lowered its target price for OmniAb shares from $4.00 to $3.00, maintaining an "outperform" rating. Institutional investors have been active, with several hedge funds buying or boosting stakes in the company.
OmniAb to Report Third Quarter 2025 Financial Results on November 4 - PharmiWeb.com
OmniAb, Inc. will report its financial results for the three and nine months ended September 30, 2025, after the U.S. financial markets close on Tuesday, November 4, 2025. The company will also host a conference call on the same day at 4:30 p.m. Eastern time to discuss the results and provide business updates. OmniAb specializes in licensing discovery research technology for next-generation therapeutics, utilizing its Biological Intelligence™ platform for antibody and target-binding protein discovery.
OmniAb to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
OmniAb, Inc. (NASDAQ: OABI) announced its management will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, with one-on-one meetings scheduled for September 9th. The company aims to connect with investors and highlight its cutting-edge discovery research technology, which leverages diverse antibody repertoires and proprietary transgenic animals to identify optimal antibodies for therapeutic development. OmniAb's business model includes upfront fees, service revenue, milestones, and royalties on commercial sales.
OmniAb stock falls after announcing $30 million private placement
OmniAb Inc. (NASDAQ:OABI) stock fell significantly after the company announced a private placement of over 21.25 million shares at $1.40 each, with officers and directors purchasing at a higher price of $1.85. The placement is expected to generate approximately $30 million for general corporate purposes. The market reacted negatively due to the substantial dilution of existing shareholders at a price below recent trading levels.
Earnings call transcript: OmniAb Q2 2025 sees revenue decline amid restructuring
OmniAb, Inc. reported a significant revenue decline in Q2 2025 to $3.9 million from $7.6 million year-over-year, alongside a net loss of $15.9 million. Despite these financial challenges, the company launched a new Exploration Partner Access Program and maintained its 2025 revenue guidance of $20 million to $25 million, emphasizing strategic initiatives and cost-saving measures. Analysts view the stock as undervalued with a strong buy consensus and a potential upside of 290%.
OmniAb Inc. publie ses résultats pour le trimestre clos le 30 juin - Résumé des bénéfices
OmniAb Inc. (OABI) reported an adjusted quarterly loss of 15 cents per share for the quarter ending June 30, which met the average analyst forecast. Revenues decreased by 48.8% year-over-year to $3.90 million, falling short of analysts' expectations of $5.33 million. Despite the revenue miss, analysts maintain an "buy" rating on the stock with a median 12-month price target of $8.50.
Positive week for OmniAb, Inc. (NASDAQ:OABI) institutional investors who lost 49% over the past year
OmniAb, Inc. (NASDAQ:OABI) saw a positive week for institutional investors, with a 12% share price increase, despite a 49% loss over the past year. Institutions collectively hold 49% ownership, with Avista Healthcare Partners being the largest shareholder at 13%. Insiders own 2.8% of the company, showing alignment, while the general public holds a 27% stake.
Angelini Advances Brain Health Ambitions With GRIN Pact
Angelini Pharma has strengthened its position in brain health with a new agreement with GRIN Therapeutics Inc. This partnership is expected to further Angelini's ambitions in the neuro-related therapeutic area. The article highlights this strategic move by Angelini within the pharmaceutical business landscape.
